Biocon Biologics set to ramp up production of itolizumab2 min read . Updated: 14 Jul 2020, 06:57 AM IST
Mazumdar-Shaw and Sandeep Athalye, Biocon Biologics’ senior VP and chief medical officer, defend the drug against experts’ criticism regarding the small number of participants in the study
NEW DELHI : Biocon Biologics India Ltd will ramp up its capacity to produce itolizumab to avoid any shortage of the drug, which received approval from the Drug Controller General of India (DCGI) late last week for the treatment of a critical covid-19 symptom called cytokine storm, Biocon chairperson Kiran Mazumdar-Shaw said on Monday.
Select your Category